Sign up to save your podcasts
Or
Share JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.
View all episodes
By The JAMA Network
4.9
1212 ratings
Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.
More shows like JAMA Network
View all
JAMA Editors' Summary
129 Listeners
Neurology® Podcast
287 Listeners
NEJM This Week
314 Listeners
JAMA Author Interviews
162 Listeners
Diabetes Core Update
99 Listeners
Practical Neurology Podcast
36 Listeners
JAMA Clinical Reviews
485 Listeners
Mayo Clinic Talks
271 Listeners
JAMA Cardiology Author Interviews
9 Listeners
JAMA Dermatology Author Interviews
17 Listeners
JAMA Internal Medicine Author Interviews
18 Listeners
JAMA Psychiatry Author Interviews
23 Listeners
JAMA Medical News
83 Listeners
Core IM | Internal Medicine Podcast
1,091 Listeners
Psychiatry & Psychotherapy Podcast
1,319 Listeners
JAMAevidence The Rational Clinical Examination
29 Listeners
Annals On Call Podcast
183 Listeners
The Clinical Problem Solvers
507 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
JAMAevidence JAMA Guide to Statistics and Methods
19 Listeners
The Curious Clinicians
360 Listeners
AMA Update
99 Listeners